NEWS

Dyna Therapeutics, subsidiary of Bukwang, registered patent of anticancer drug...

[July 22, 2020]

Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to Japan Patent Office on 21st July 2020. With registration of this patent, the composition of SOL-804 will be protected until 2035 in Japan. Additionally, the patent application is currently under examination in various countries, including Korea, USA, Europe, China, India, Eurasia and others. Dyna is Bukwang’s 100% owned subsidiary which was...

R&D

Dyna Therapeutics, subsidiary of Bukwang, registered patent of anticancer drug SOL-804...

[July 22, 2020]

Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered composition patent for anti-cancer drug...

PRODUCTS
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square